title: Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
abstract: Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3 Chome-25-8 Nishishinbashi, Minato, Tokyo 105-0003, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Saruta
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: Papadakis.Konstantinos@mayo.edu.
authors.forename: Konstantinos A
authors.initials: KA
authors.lastname: Papadakis
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D016023:Integrins / Q000037:antagonists & inhibitors*; D018799:Intercellular Adhesion Molecule-1; D009088:Mucoproteins / Q000037:antagonists & inhibitors; D000069442:Natalizumab; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D054735:Phosphorothioate Oligonucleotides / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D054388:Receptors, CCR / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: C000588820:AJM300; D061067:Antibodies, Monoclonal, Humanized; C119309:CC chemokine receptor 9; C583420:CCX282-B; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents; D007136:Immunoglobulins; D016023:Integrins; C504265:MADCAM1 protein, human; D009088:Mucoproteins; D000069442:Natalizumab; D054735:Phosphorothioate Oligonucleotides; D052999:Quinazolinones; D054388:Receptors, CCR; D013449:Sulfonamides; D018799:Intercellular Adhesion Molecule-1; D010649:Phenylalanine; C000597368:ontamalimab; C543529:vedolizumab; C559198:etrolizumab; C089753:alicaforsen
keywords: Chemokine receptors; Crohn disease; Etrolizumab; Inflammatory bowel disease; Integrins; Natalizumab; Ulcerative colitis; Vedolizumab